|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.311 SEK | -9.06% |
|
-5.76% | -64.66% |
| 04-09 | Biosergen to Issue New Units as Compensation Under Rights Issue | MT |
| 03-27 | Biosergen Raises SEK26.4 Million via Rights Issue | MT |
Biosergen AB reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 9.38 million compared to SEK 5.18 million a year ago. Net loss was SEK 27.04 million compared to SEK 39.91 million a year ago.
Basic loss per share from continuing operations was SEK 0.53 compared to SEK 1.28 a year ago. Diluted loss per share from continuing operations was SEK 0.53 compared to SEK 1.28 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.66% | 4.5M | |
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B |
BIOSERGEN AB 